Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Cardiomyopathies in children

  • Hong, Young Mi (Department of Pediatrics, Ewha Womans University School of Medicine)
  • Received : 2012.09.21
  • Accepted : 2013.01.04
  • Published : 2013.02.15
Download PDF
⟨ Previous Next ⟩

Abstract

Cardiomyopathy (CMP) is a heterogeneous disease caused by a functional abnormality of the cardiac muscle. CMP is of 2 major types, dilated and hypertrophic, and is further classified as either primary or secondary. Secondary CMP is caused by extrinsic factors, including infection, ischemia, hypertension, and metabolic disorders. Primary CMP is diagnosed when the extrinsic factors of secondary CMP are absent. Furthermore, the World Health Organization, American Heart Association, and European Cardiology Association have different systems for clinically classifying primary CMP. Primary CMP is rare and associated with a family history of the disease, implying that genetic factors might affect its incidence. In addition, the incidence of CMP varies widely according to patient ethnicity. Genetic testing plays an important role in the care of patients with CMP and their families because it confirms diagnosis, determines the appropriate care for the patient, and possibly affects patient prognosis. The diagnosis and genetic identification of CMP in patients' families allow the possibility to identify novel genes that may lead to new treatments. This review focuses on the epidemiology, pathophysiology, diagnosis, and treatment of CMP, with the aim of providing pediatricians with insights that may be helpful in the early identification and management of idiopathic CMP in children.

Keywords

References

  1. Wilkinson JD, Landy DC, Colan SD, Towbin JA, Sleeper LA, Orav EJ, et al. The pediatric cardiomyopathy registry and heart failure: key results from the first 15 years. Heart Fail Clin 2010;6:401-13. https://doi.org/10.1016/j.hfc.2010.05.002
  2. Bilgic A, Ozbarlas N, Ozkutlu S, Ozer S, Ozme S. Cardiomyopathies in children. Clinical, epidemiological and prognostic evaluation. Jpn Heart J 1990;31:789-97. https://doi.org/10.1536/ihj.31.789
  3. Arola A, Jokinen E, Ruuskanen O, Saraste M, Pesonen E, Kuusela AL, et al. Epidemiology of idiopathic cardiomyopathies in children and adolescents: a nationwide study in Finland. Am J Epidemiol 1997;146:385-93. https://doi.org/10.1093/oxfordjournals.aje.a009291
  4. Oh JH, Hong YM, Choi JY, Kim SJ, Jung JW, Sohn S, et al. Idiopathic cardiomyopathies in Korean children: 9-year Korean multicenter study. Circ J 2011;75:2228-34. https://doi.org/10.1253/circj.CJ-11-0051
  5. Jefferies JL, Towbin JA. Dilated cardiomyopathy. Lancet 2010;375: 752-62. https://doi.org/10.1016/S0140-6736(09)62023-7
  6. Taylor MR, Carniel E, Mestroni L. Cardiomyopathy, familial dilated. Orphanet J Rare Dis 2006;1:27. https://doi.org/10.1186/1750-1172-1-27
  7. Moak JP, Kaski JP. Hypertrophic cardiomyopathy in children. Heart 2012;98:1044-54. https://doi.org/10.1136/heartjnl-2011-300531
  8. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996;93:841-2. https://doi.org/10.1161/01.CIR.93.5.841
  9. Giles TD. New WHO/ISFC classification of cardiomyopathies: a task not completed. Circulation 1997;96:2081-2.
  10. Thiene G, Corrado D, Basso C. Cardiomyopathies: is it time for a molecular classification? Eur Heart J 2004;25:1772-5. https://doi.org/10.1016/j.ehj.2004.07.026
  11. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006;113:1807-16. https://doi.org/10.1161/CIRCULATIONAHA.106.174287
  12. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270-6.
  13. Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003;348:1647-55. https://doi.org/10.1056/NEJMoa021715
  14. Nugent AW, Daubeney PE, Chondros P, Carlin JB, Cheung M, Wilkinson LC, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003;348:1639-46. https://doi.org/10.1056/NEJMoa021737
  15. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006;296:1867-76. https://doi.org/10.1001/jama.296.15.1867
  16. Towbin JA, Bowles NE. The failing heart. Nature 2002;415:227-33. https://doi.org/10.1038/415227a
  17. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001; 104:557-67. https://doi.org/10.1016/S0092-8674(01)00242-2
  18. Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med 2008;5:158-68. https://doi.org/10.1038/ncpcardio1110
  19. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308-20.
  20. Semsarian C; CSANZ Cardiac Genetics Diseases Council Writing Group. Guidelines for the diagnosis and management of hypertrophic cardiomyopathy. Heart Lung Circ 2011;20:688-90. https://doi.org/10.1016/j.hlc.2011.07.017
  21. Montgomery JV, Harris KM, Casey SA, Zenovich AG, Maron BJ. Relation of electrocardiographic patterns to phenotypic expression and clinical outcome in hypertrophic cardiomyopathy. Am J Cardiol 2005;96:270-5. https://doi.org/10.1016/j.amjcard.2005.03.058
  22. Maron BJ, McKenna WJ, Elliott P, Spirito P, Frenneaux MP, Keren A, et al. Hypertrophic cardiomyopathy. JAMA 1999;282:2302-3. https://doi.org/10.1001/jama.282.24.2302
  23. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995;26:1699-708. https://doi.org/10.1016/0735-1097(95)00390-8
  24. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol 1981;48:418-28. https://doi.org/10.1016/0002-9149(81)90068-0
  25. Maron BJ. Hypertrophic cardiomyopathy in childhood. Pediatr Clin North Am 2004;51:1305-46. https://doi.org/10.1016/j.pcl.2004.04.017
  26. Nugent AW, Daubeney PE, Chondros P, Carlin JB, Colan SD, Cheung M, et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population- based study. Circulation 2005;112:1332-8. https://doi.org/10.1161/CIRCULATIONAHA.104.530303
  27. Ho CY, Carlsen C, Thune JJ, Havndrup O, Bundgaard H, Farrohi F, et al. Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy. Circ Cardiovasc Genet 2009;2:314-21.
  28. McMahon CJ, Nagueh SF, Pignatelli RH, Denfield SW, Dreyer WJ, Price JF, et al. Characterization of left ventricular diastolic function by tissue Doppler imaging and clinical status in children with hypertrophic cardiomyopathy. Circulation 2004;109:1756-62. https://doi.org/10.1161/01.CIR.0000124723.16433.31
  29. Menon SC, Ackerman MJ, Cetta F, O'Leary PW, Eidem BW. Significance of left atrial volume in patients <20 years of age with hypertrophic cardiomyopathy. Am J Cardiol 2008;102:1390-3. https://doi.org/10.1016/j.amjcard.2008.07.027
  30. Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005;112: 855-61. https://doi.org/10.1161/CIRCULATIONAHA.104.507723
  31. Germans T, Wilde AA, Dijkmans PA, Chai W, Kamp O, Pinto YM, et al. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol 2006;48:2518-23. https://doi.org/10.1016/j.jacc.2006.08.036
  32. Price JF, Thomas AK, Grenier M, Eidem BW, O'Brian Smith E, Denfield SW, et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 2006;114:1063-9. https://doi.org/10.1161/CIRCULATIONAHA.105.608869
  33. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 2007;50:1914-31. https://doi.org/10.1016/j.jacc.2007.09.008
  34. Bowles NE, Ni J, Kearney DL, Pauschinger M, Schultheiss HP, McCarthy R, et al. Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003;42:466-72. https://doi.org/10.1016/S0735-1097(03)00648-X
  35. Harmon WG, Sleeper LA, Cuniberti L, Messere J, Colan SD, Orav EJ, et al. Treating children with idiopathic dilated cardiomyopathy (from the Pediatric Cardiomyopathy Registry). Am J Cardiol 2009;104:281-6. https://doi.org/10.1016/j.amjcard.2009.03.033
  36. Grenier MA, Fioravanti J, Truesdell SC, Mendelsohn AM, Vermilion RP, Lipshultz SE. Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: a review. Prog Pediatr Cardiol 2000;12:91-111. https://doi.org/10.1016/S1058-9813(00)00061-8
  37. Ostman-Smith I. Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death. Fundam Clin Pharmacol 2010;24:637-52. https://doi.org/10.1111/j.1472-8206.2010.00869.x
  38. Maskatia SA. Hypertrophic cardiomyopathy: infants, children, and adolescents. Congenit Heart Dis 2012;7:84-92. https://doi.org/10.1111/j.1747-0803.2011.00613.x
  39. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-85. https://doi.org/10.1056/NEJM199703133361107
  40. Frazier OH, Rose EA, Oz MC, Dembitsky W, McCarthy P, Radovancevic B, et al. Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 2001;122:1186-95. https://doi.org/10.1067/mtc.2001.118274
  41. Liu J, Sluijter JP, Goumans MJ, Smits AM, van der Spoel T, Nathoe H, et al. Cell therapy for myocardial regeneration. Curr Mol Med 2009;9:287-98. https://doi.org/10.2174/156652409787847218
  42. Vinge LE, Raake PW, Koch WJ. Gene therapy in heart failure. Circ Res 2008;102:1458-70. https://doi.org/10.1161/CIRCRESAHA.108.173195
  43. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR- AMI trial. Eur Heart J 2006;27:2775-83. https://doi.org/10.1093/eurheartj/ehl388
  44. Decker JA, Rossano JW, Smith EO, Cannon B, Clunie SK, Gates C, et al. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. J Am Coll Cardiol 2009;54:250-4. https://doi.org/10.1016/j.jacc.2009.03.051
  45. Ostman-Smith I, Wettrell G, Keeton B, Riesenfeld T, Holmgren D, Ergander U. Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly. Cardiol Young 2005;15:632-42. https://doi.org/10.1017/S1047951105001824
  46. Maron BJ, Douglas PS, Graham TP, Nishimura RA, Thompson PD. Task Force 1: preparticipation screening and diagnosis of cardiovascular disease in athletes. J Am Coll Cardiol 2005;45: 1322-6. https://doi.org/10.1016/j.jacc.2005.02.007
  47. Charron P, Arad M, Arbustini E, Basso C, Bilinska Z, Elliott P, et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2010;31:2715-26. https://doi.org/10.1093/eurheartj/ehq271

Cited by

  1. Role of Cardiac Magnetic Resonance in the Evaluation of Dilated Cardiomyopathy: Diagnostic Contribution and Prognostic Significance vol.2014, pp.None, 2013, https://doi.org/10.1155/2014/365404
  2. Magnetic resonance tagging for diagnosis of focal hypertrophic cardiomyopathy in a child vol.57, pp.3, 2013, https://doi.org/10.1111/ped.12499
  3. Cardiovascular magnetic resonance: Diagnostic utility and specific considerations in the pediatric population vol.5, pp.1, 2013, https://doi.org/10.5409/wjcp.v5.i1.1
  4. Childhood Cardiomyopathies: A Study in Tertiary Care Hospital in Upper Egypt vol.8, pp.11, 2013, https://doi.org/10.19082/3164
  5. Delayed myocardial enhancement in children with different types of cardiomyopathy: a diagnostic and prognostic tool vol.50, pp.1, 2013, https://doi.org/10.1186/s43055-019-0035-6